PWSHub News

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

Astrazeneca (AZN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this pharmaceutical have returned -10.3% over the past month versus the Zacks S&P 500 composite's +5.8% change. The Zacks Large Cap Pharmaceuticals industry, to which Astrazeneca belongs, has gained 5.4% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate Revisions

Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Astrazeneca is expected to post earnings of $0.85 per share for the current quarter, representing a year-over-year change of -11.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +9.7%.

For the current fiscal year, the consensus earnings estimate of $4.09 points to a change of +12.7% from the prior year. Over the last 30 days, this estimate has changed -2.2%.

For the next fiscal year, the consensus earnings estimate of $5.05 indicates a change of +23.4% from what Astrazeneca is expected to report a year ago. Over the past month, the estimate has changed -3.4%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Astrazeneca.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth Forecast

While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Astrazeneca, the consensus sales estimate for the current quarter of $12.09 billion indicates a year-over-year change of +11.1%. For the current and next fiscal years, $50.82 billion and $55.38 billion estimates indicate +10.9% and +9% changes, respectively.

Last Reported Results and Surprise History

Astrazeneca reported revenues of $12.02 billion in the last reported quarter, representing a year-over-year change of +7.3%. EPS of $0.73 for the same period compares with $0.69 a year ago.

Compared to the Zacks Consensus Estimate of $12.07 billion, the reported revenues represent a surprise of -0.42%. The EPS surprise was -1.35%.

Over the last four quarters, Astrazeneca surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

Valuation

No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Astrazeneca is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Conclusion

The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Astrazeneca. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Source: finance.yahoo.com

Related stories
1 week ago - First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting Positive high-level results...
2 weeks ago - Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and Wegovy. Lilly's share price has soared...
3 weeks ago - Looking for some deals in the stock market? If you've got $5,000 that you are looking to invest in some established growth stocks, there are some...
1 month ago - Sizzling hot. Those two words accurately describe the performances of the Nasdaq Composite and the Nasdaq-100 last year. The latter index, which comprises the 100 biggest non-financial Nasdaq stocks, delivered its best return since 1999...
Other stories
12 minutes ago - PayPal is down 80% from its all-time high and trades at a dirt-cheap valuation as it enters a "transition year."
21 minutes ago - Sports gambling companies like DraftKings and FanDuel are expanding way beyond football and basketball into online gambling and the lottery.
22 minutes ago - More than one million people died just in the U.S. as a result of the COVID-19 pandemic that broke out in 2020. But a scientific miracle – a vaccine released later that same year – saved countless lives. Last year Katalin Karikó and Drew...
22 minutes ago - Some members of oil cartel OPEC, led by Saudi Arabia, and allied producers like Russia are again deepening their voluntary crude supply cuts.
42 minutes ago - Super Micro Computer (NASDAQ: SMCI) was a big winner last month. The maker of storage and server systems that are highly valued for...
52 minutes ago - Fisker is stopping work on new electric vehicles until it partners with another automaker.The company announced its plans alongside its 2023 and Q4...